Align Technology, Inc. vs Nasdaq100 ETF — how do they compare? Align Technology, Inc. trades at $182.11 (market cap $12.86B), while Nasdaq100 ETF trades at $716.92. The key difference: Nasdaq100 ETF is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | QQQ | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | — |
52-Week High | $207.19 | $746.16 |
52-Week Low | $124.88 | $553.88 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
QQQ trades at $725.54, up 0.32% with a bullish technical signal from moving averages. Support lies at $718 and resistance at $727. The ETF faces new competition from BlackRock's IQQ but maintains strong Nasdaq-100 exposure. Recent news highlights its role in growth portfolios and hedging strategies using SQQQ.
Outlook remains mixed with 50% analyst buy ratings. Key risks include market volatility and competitive ETF launches. Upside potential hinges on tech sector performance, while downside protection strategies are gaining attention among investors.
Trailing returns across standard periods
Latest headlines on both assets
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →